patiromer calcium 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	5056	1415477-49-4

Description:

Molecule	Description
Synonyms: patiromer calcium patiromer sorbitex calcium veltassa RLY5016S patiromer RLY5016 patiromer glucitol calcium	binds potassium ions in the gastrointestinal tract to lower serum potassium levels Molecular weight: Formula: (C34H52CaO16(C2H3)n(C2H2F)m(C2H3)n(C2H3)p(C2H3)p)x CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

patiromer calcium
patiromer sorbitex calcium
veltassa
RLY5016S
patiromer
RLY5016
patiromer glucitol calcium

binds potassium ions in the gastrointestinal tract to lower serum potassium levels

Molecular weight:
Formula: (C34H52CaO16(C2H3)n(C2H2F)m(C2H3)n(C2H3)p(C2H3)p)x
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
8.40	g	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Oct. 21, 2015	FDA	RELYPSA INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Death	629.98	42.42	358	3809	341068	55946832
Hospitalisation	413.62	42.42	168	3999	74832	56213068
Blood potassium increased	290.88	42.42	89	4078	17172	56270728
Constipation	239.21	42.42	161	4006	201782	56086118
Product dose omission issue	197.37	42.42	144	4023	204609	56083291
Loss of employment	135.92	42.42	31	4136	1906	56285994
Product colour issue	133.53	42.42	25	4142	573	56287327
Off label use	118.65	42.42	173	3994	556007	55731893
No adverse event	107.93	42.42	53	4114	36321	56251579
Dialysis	101.88	42.42	35	4132	9667	56278233
Product taste abnormal	99.71	42.42	24	4143	1864	56286036
Inappropriate schedule of product administration	92.26	42.42	64	4103	83323	56204577
Diarrhoea	85.18	42.42	161	4006	638346	55649554
Hepatic steatosis	65.42	42.42	34	4133	26180	56261720
Gastric disorder	63.22	42.42	36	4131	33174	56254726
Cardiac failure congestive	60.85	42.42	51	4116	87669	56200231
Product solubility abnormal	57.46	42.42	13	4154	769	56287131
Flatulence	57.10	42.42	33	4134	31255	56256645
Abdominal pain upper	57.04	42.42	68	4099	178245	56109655
Abdominal discomfort	56.81	42.42	85	4082	277189	56010711
Product physical issue	46.03	42.42	16	4151	4566	56283334
Malaise	45.30	42.42	90	4077	367770	55920130

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Death	914.27	39.41	556	3454	360013	31333321
Hospitalisation	555.77	39.41	215	3795	49592	31643742
Constipation	417.41	39.41	233	3777	123758	31569576
Product dose omission issue	299.76	39.41	178	3832	105408	31587926
Blood potassium increased	293.37	39.41	99	3911	15246	31678088
Dialysis	185.21	39.41	64	3946	10539	31682795
Product taste abnormal	110.19	39.41	26	3984	1075	31692259
Off label use	103.23	39.41	168	3842	347106	31346228
Inappropriate schedule of product administration	99.29	39.41	68	3942	50755	31642579
Flatulence	86.65	39.41	44	3966	18904	31674430
Product colour issue	80.17	39.41	17	3993	428	31692906
No adverse event	76.64	39.41	41	3969	19584	31673750
Diarrhoea	71.88	39.41	145	3865	352264	31341070
Abdominal discomfort	66.94	39.41	54	3956	51513	31641821
Product physical issue	56.93	39.41	18	3992	2237	31691097
Product solubility abnormal	56.82	39.41	13	3997	468	31692866
Treatment noncompliance	51.57	39.41	35	3975	25649	31667685

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Death	1004.50	42.24	583	5404	509478	70412979
Hospitalisation	495.07	42.24	204	5783	82364	70840093
Constipation	414.02	42.24	259	5728	252179	70670278
Product dose omission issue	378.76	42.24	232	5755	217236	70705221
Blood potassium increased	353.71	42.24	119	5868	27207	70895250
Off label use	187.53	42.24	268	5719	742792	70179665
Loss of employment	127.10	42.24	31	5956	2228	70920229
Dialysis	124.52	42.24	49	5938	17353	70905104
Inappropriate schedule of product administration	121.49	42.24	88	5899	107467	70814990
Abdominal discomfort	120.17	42.24	117	5870	214541	70707916
Diarrhoea	117.56	42.24	224	5763	783117	70139340
Flatulence	113.11	42.24	58	5929	38123	70884334
Product taste abnormal	108.48	42.24	27	5960	2109	70920348
Product colour issue	78.51	42.24	17	5970	718	70921739
Abdominal pain upper	76.93	42.24	88	5899	193514	70728943
Product solubility abnormal	75.48	42.24	17	5970	862	70921595
Gastric disorder	74.49	42.24	42	5945	33280	70889177
Cardiac failure congestive	59.63	42.24	65	5922	135392	70787065
Product physical issue	59.33	42.24	19	5968	3695	70918762
No adverse event	57.29	42.24	35	5952	32118	70890339
Hepatic steatosis	53.17	42.24	34	5953	33779	70888678
Malaise	48.22	42.24	110	5877	432822	70489635
Treatment noncompliance	43.36	42.24	34	5953	46540	70875917

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V03AE09	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Drugs for treatment of hyperkalemia and hyperphosphatemia
FDA MoA	N0000178377	Potassium Ion Binding Activity
FDA EPC	N0000178378	Potassium Binder

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hyperkalemia	indication	14140009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 16.8GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	10485821	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8287847	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8475780	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8778324	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8889115	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	10485821	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8287847	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8475780	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8778324	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8889115	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	10485821	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8287847	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8475780	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8778324	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8889115	March 30, 2024	TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	7556799	Feb. 27, 2025	TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	7556799	Feb. 27, 2025	TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	7556799	Feb. 27, 2025	TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8216560	March 14, 2027	TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8216560	March 14, 2027	TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8216560	March 14, 2027	TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8337824	May 29, 2030	TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8337824	May 29, 2030	TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	8337824	May 29, 2030	TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	11123363	Oct. 8, 2033	TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	9492476	Oct. 8, 2033	TREATMENT OF HYPERKALEMIA
EQ 16.8GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	9925212	Oct. 8, 2033	TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	11123363	Oct. 8, 2033	TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	9492476	Oct. 8, 2033	TREATMENT OF HYPERKALEMIA
EQ 25.2GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	9925212	Oct. 8, 2033	TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	11123363	Oct. 8, 2033	TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	9492476	Oct. 8, 2033	TREATMENT OF HYPERKALEMIA
EQ 8.4GM BASE/PACKET	VELTASSA	VIFOR PHARMA	N205739	Oct. 21, 2015	RX	POWDER	ORAL	9925212	Oct. 8, 2033	TREATMENT OF HYPERKALEMIA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
7T97I3787N	UNII
D10149	KEGG_DRUG
1208912-84-8	SECONDARY_CAS_RN
1260643-52-4	SECONDARY_CAS_RN
C4301626	UMLSCUI
CHEMBL2107840	ChEMBL_ID
CHEMBL2107875	ChEMBL_ID
9532	INN_ID
C568789	MESH_SUPPLEMENTAL_RECORD_UI
DB09263	DRUGBANK_ID
1716203	RXNORM
236636	MMSL
31246	MMSL
d08388	MMSL
016559	NDDF
016560	NDDF
715260008	SNOMEDCT_US
763550001	SNOMEDCT_US
4035186	VANDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
VELTASSA	HUMAN PRESCRIPTION DRUG LABEL	1	53436-084	POWDER, FOR SUSPENSION	8.40 g	ORAL	NDA	26 sections
VELTASSA	HUMAN PRESCRIPTION DRUG LABEL	1	53436-168	POWDER, FOR SUSPENSION	16.80 g	ORAL	NDA	26 sections
VELTASSA	HUMAN PRESCRIPTION DRUG LABEL	1	53436-252	POWDER, FOR SUSPENSION	25.20 g	ORAL	NDA	26 sections